**IN THE SPECIFICATION**

Page 11, replace the first paragraph starting at line 3 with the following:

The vaccine may be formulated using known techniques for formulating attenuated bacterial vaccines. The vaccine is advantageously presented for oral administration, for example in a lyophilised encapsulated form. Such capsules may be provided with an enteric coating comprising, for example, EUDRAGIT "S" (Trade Mark), anionic polymer of methacrylic acid and methacrylates with a –COOH group, EUDRAGIT "L" (Trade Mark) anionic polymer of methacrylic acid and methacrylates with a –COOH group, cellulose acetate, cellulose phthalate or hydroxypropylmethyl cellulose. These capsules may be used as such, or alternatively, the lyophilised material may be reconstituted prior to administration, e.g. as a suspension. Reconstitution is advantageously effected in a buffer at a suitable pH to ensure the viability of the bacteria. In order to protect the attenuated bacteria and the vaccine from gastric acidity, a sodium bicarbonate preparation is advantageously administered before each administration of the vaccine. Alternatively, the vaccine may be prepared for parenteral administration, intranasal ~~20~~ administration or intramuscular administration.